Sodium/glucose cotransporter 2 inhibitors in patients with diabetes mellitus and chronic kidney disease: Turning the page

Circulation

Volumn 137, Issue 2, 2018, Pages 130-133

  Plutzky, Jorge ^a   Bakris, George ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Editorials; Kidney diseases

Indexed keywords

CANAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; LIRAGLUTIDE; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; BENZHYDRYL DERIVATIVE; GLUCOSE; GLUCOSIDE; SODIUM;

ALBUMINURIA; AMINO ACID METABOLISM; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BODY WEIGHT LOSS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY STENTING; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; ESTIMATED GLOMERULAR FILTRATION RATE; GLUCOSURIA; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HYPERGLYCEMIA; INSULIN TREATMENT; KIDNEY TUBULE ABSORPTION; MEDICAL HISTORY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SURVIVAL; SURVIVOR; CARDIOVASCULAR DISEASE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSIDES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; SODIUM;

EID: 85043715672     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.031422     Document Type: Review

References (15)

1. Bliss M. The history of insulin. Diabetes Care. 1993;16(suppl 3):4-7.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234. doi: 10.1056/NEJM199807233390404.
3. Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? Circulation. 2002;106:2760-2763.
4. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
5. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322. doi: 10.1056/NEJMoa1603827.
6. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. doi: 10.1056/NEJMoa1607141.
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.
8. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi: 10.1056/NEJMoa1611925.
9. Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26:27-38. doi: 10.1016/j. cmet.2017.04.011.
10. Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; on behalf of the EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119-129. doi: 10.1161/CIRCULATIONAHA.117.028268.
11. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238-1252. doi: 10.1016/S0140-6736(16)32064-5.
12. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807-814. doi: 10.1016/S0140-6736(12)60572-8.
13. Wanner C. EMPA-REG OUTCOME: the nephrologist's point of view. Am J Med. 2017;130:S63-S72. doi: 10.1016/j.amjmed.2017.04.007.
14. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772. doi: 10.1161/CIRCULATIONAHA.116.021887.
15. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25:262-284. doi: 10.1016/j.cmet.2016.12.022.